Chinese Governemt Deligation Came to Meet Giostar San Diago California
GIOSTAR will bring team of experts from USA to develop the advance stem cell transplant program at San Vicente Foundation Hospital. This collaboration will bring the country of Columbia in par with USA in regards to availability of the advance stem cell transplant for many incurable diseases.
This much needed collaboration with two private organizations from USA and Columbia will be the blessings for the people of Columbia and synergistically aligns with the core values of San Vicente Foundation.
Dr. Anand Shrivastava, Chairman – GIOSTAR U.S.A. Presenting the GUSI Peace Prize 2015 to Former Health Minister of China Dr. Huang Jiefu for Human Rights
Dr. A. S. Srivastava
Stem Cell Core Labratory
Salk Institute for Biological Studies La Jolla
Dear Dr. Srivastava,
On behalf of the editorial board of “Current Pharmaceutical Design”, I would like to propose your name to be considered as an Executive Guest Editor for a thematic issue of the journal in a hot topic area.
“Current Pharmaceutical Design” is a leading international journal, which publishes frontier reviews in important fields of drug discovery. The journal is published by Bentham Science Publishers and has been widely acclaimed because of its excellent standards and the high quality of publications. It is abstracted/indexed in a number of major abstracting/indexing agencies, Impact Factor: 6.452 (2014 SCI Journal Citation Reports). Each issue is published under a Guest Editor who is an authority in the field and who is responsible for soliciting top class articles covering various important aspects of the field from leading authorities.
Bentham Science Publishers is currently publishing 42 issues of the journal annually. These “theme issues” contain articles in important fields of current research activity written by eminent experts in the field. The Guest Editor is responsible for soliciting top class articles covering various important aspects of the selected topic from leading authorities in the field. In view of current demand for the journal, the publishers are soliciting additional topic themes relevant to pharmaceutical design. Please visit the website of Current Pharmaceutical Design for more information.
If you are interested in being considered for the post of Executive Guest Editor, then please send us the following:
1. Title of your topic or theme.
2. List of authors (along with their affiliation) and the titles of the articles they are contributing.
3. Brief introduction of the issue.
4. A description stating how the subject will contribute to the field.
5. Your complete CV and detailed list of publications.
The aim of the journal is to provide readers with comprehensive accounts of recent developments in the frontier areas of the field. The articles should take the form of full-length manuscripts of recent developments in important areas related to pharmaceutical design within a therapeutic field. They could include accounts of the author’s research work combined with a review of the recent literature so that the readers will not only have the opportunity of benefiting from the author’s contribution, but will also gain access to a broader perspective of the field.
We will need to have about 250-300 printed pages in the journal issue from about 10-15 authors who are leading experts in the field (for manuscript preparation details please visit Author Guidelines Please note that no research articles will be accepted as a part of the thematic issue.
As the Executive Guest Editor, you will be required to contribute a one-page foreword highlighting the importance of the chosen topic and of the articles contained in the issue. You may also contribute an article to the issue yourself. You will be entitled to free online subscription to the whole volume of the journal for the year in which your issue has appeared. Appointment as the Executive Guest Editor is renewable by mutual agreement.
I would be grateful if you could please send your reply to me at email@example.com. as soon as possible along with the choice of the proposed theme/ topic area of your interest.
I shall be looking forward to receiving your positive reply.
Prof. William A. Banks
Editor-in-Chief Current Pharmaceutical Design
Researchers found that after testing five SCID-X1 patients who received both gene therapy and low-dose chemotherapy, four of the patients showed improvements in immune function. Scientists from the National Institute of Allergy and Infectious Diseases (NIAID) have come up with a new gene therapy that can restore immunity…
The standard treatment would include a transplant of stem cells, which can be obtained from the direct family members. Only one of them unfortunately perished, due to a pre-existing condition that damaged their lungs before the new therapy could be applied. Currently, patients suffering from SCID-X1 are treated with stem cell transplants.
The National Institute of Allergy and Infectious Diseases reports a procedure including the extraction, genetic correction and reinsertion of a patient’s bone marrow can help their immune systems improve over time.
SCID-X1 is generally triggered by mutations in the IL2RG gene that averts infection-fighting immune cells from developing and working normally, leaving inflicted children highly vulnerable to life-threatening infections. One of the lifesaving treatments for very young children with SCID-X1 is transplantation of stem cells, ideally from a sibling donor who is genetically matched.
In the latest study, scientists examined the safety and effectiveness of gene therapy pooled with low-dose chemotherapy in five SCID-X1 patients.
Using a lentiviral vector, the scientists included a healthy IL2RG gene in the stem cells. The patients were then given low-dose chemotherapy to eliminate the defective blood cells. One patient received treatment three years ago with continued improvements. Another patient is doing well and continues to show improvement even after three years of the gene therapy. Three more patients aged 7 to 24 are improving, though it has only been three to six months since the treatment was performed. All surviving patients are continually being monitored.
Severe Combined Immunodeficiency is a rare immunodeficiency that leads to frequent serious infections. They manipulated the virus gene to deliver the right gene to the cell. By collecting an individual s stem cells and modifying them with a lentivirus, the gene-corrected cells can be returned into the blood to help produce normal healthy immune cells. Accessible treatments for this once-deadly disorder have centered around bone marrow transplants, yet encouraging results have been reported by an on-going clinical trial for an emerging gene therapy – Lentiviral gene transfer.
To determine the safety and effectiveness of lentiviral gene transfer as a treatment for children and adolescents with X-linked severe combined immunodeficiency.
Resource : http://goo.gl/nUrAFf